Oral solid medicine composition for nervous system diseases

A technology of adhesives and tablets, which can be used in nervous system diseases, drug combinations, cardiovascular system diseases, etc., can solve the problems of left ventricular enlargement and reduction, achieve elimination half-life, low toxic and side effects, and improve brain energy metabolism. Effect

Active Publication Date: 2013-04-17
北京利龄恒泰药业有限公司
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Idebenone prevented iron-induced lipid peroxidation and myocardial injury in three patients given 5 mgkg daily for 4-9 months, resulting in a reduction in left ventricular enlargement in these patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral solid medicine composition for nervous system diseases
  • Oral solid medicine composition for nervous system diseases
  • Oral solid medicine composition for nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Embodiment 1: prepare pharmaceutical composition (tablet) of the present invention

[0083] Plain Tablet Prescription:

[0084]

[0085] Preparation method:

[0086] i) Fully mix the idebenone, anhydrous lactose, and half of the disintegrant;

[0087] ii) The binder povidone K30 is made into an aqueous solution (8%), and the powder material obtained in the previous step is processed into a soft material, granulated, and dried;

[0088] iii) Mix the dried granules with the rest of the disintegrant and lubricant and / or glidant, and press it into the present invention

[0089] Tablets, which may be called tablet cores or plain tablets;

[0090] iv) Coating the tablet obtained in the above steps (Using Opadry, it is formulated into a 14% aqueous suspension immediately before use, and the coating weight increases by about 3%) to obtain a coated tablet of the pharmaceutical composition of the present invention.

Embodiment 2

[0091] Embodiment 2: prepare pharmaceutical composition (tablet) of the present invention

[0092] Plain Tablet Prescription:

[0093]

[0094] Preparation method: basically with embodiment 1. It has been determined that the weight ratio of idebenone to anhydrous lactose in the tablet is 30:80.23.

Embodiment 3

[0095] Embodiment 3: prepare pharmaceutical composition (tablet) of the present invention

[0096] Plain Tablet Prescription:

[0097]

[0098] Preparation method: basically with embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
hardnessaaaaaaaaaa
Login to view more

Abstract

The invention relates to an oral solid medicine composition for nervous system diseases. The composition is a tablet and comprises an active component, lactose anhydrous, a disintegrating agent and an adhesive. The medicine composition can be used for a cerebrovascular disease, used for improving brain metabolism and mental symptoms, activating respiratory activity of brain mitochondria, improving brain energy metabolism of brain ischemia, increasing a utilization ratio of glucose in a brain, allowing adenosine triphosphate produced in the brain to be increased, preventing brain mitochondrion from generating peroxidized lipin, and inhibiting a membrane obstruction due to lipid peroxidation of a brain mitochondrial membrane, used for brain function injures caused by the chronic cerebrovascular disease, brain trauma and the like, and used for improving mental and behavioral disorders such as a subjective symptom, a language disorder, anxiety, depression, hypomnesia and brain power declining, promoting brain power, activating a brain mitochondrion function, improving the brain energy metabolism and a brain function, improving emotion depression, low consciousness, an affective disorder, a language disorder and the like that are caused by a cerebral infarction sequela, a cerebral hemorrhage sequela and cerebral arteriosclerosis, improving brain metabolism, and protecting cranial neural cells.

Description

technical field [0001] The invention relates to an oral solid pharmaceutical composition for nervous system diseases. Background technique [0002] Neuronal damage, neurodegenerative diseases and syndromes (Alzheimer's disease, multiple sclerosis, Friedrich's ataxia, brain and spinal cord injuries and neurotrauma, stroke, Parkinson's disease, alcoholism and narcolepsy, postoperative recovery syndrome and postanesthesia recovery syndrome) and many other conditions require effective treatment and prevention. [0003] Postoperative stroke and cognitive deficit (POSCD) syndrome is common, especially in older adults undergoing major surgical procedures such as heart surgery or hip replacement. In North America, more than 2.5 million such surgical procedures are performed each year, and the incidence of POSCD exceeds 30%. There is an urgent need for interventional therapy, and there are not enough treatment options for this distressing postoperative condition. In the United Sta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/122A61K47/26A61P25/00A61P39/06A61P9/10A61P25/22A61P25/24A61P25/18A61P7/02A61P25/28A61P25/32
Inventor 刘炜
Owner 北京利龄恒泰药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap